Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease
Vascular dementia (VaD) accounts for 15–20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng C.A Mey, Ginkgo biloba L and Crocus sativus L extracts was developed...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016672/?tool=EBI |
| _version_ | 1797867155614597120 |
|---|---|
| author | Diana Karamacoska Daniel K. Y. Chan Isabella Leung Jian-xun Liu Henry Brodaty Paul P. Fahey Alan Bensoussan Dennis H. Chang |
| author_facet | Diana Karamacoska Daniel K. Y. Chan Isabella Leung Jian-xun Liu Henry Brodaty Paul P. Fahey Alan Bensoussan Dennis H. Chang |
| author_sort | Diana Karamacoska |
| collection | DOAJ |
| description | Vascular dementia (VaD) accounts for 15–20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng C.A Mey, Ginkgo biloba L and Crocus sativus L extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention. A rigorous phase III clinical trial was developed with the aim of recruiting 238 patients diagnosed with mild to moderate probable VaD, or VaD mixed with Alzheimer’s disease (where cerebrovascular disease is the clinical dominant contributor to dementia, abbreviated as CVD+AD). Using a permuted block strategy, participants will be randomly allocated to receive SLT (120 mg bd) or placebo capsules for an intervention period of 52 weeks and will be followed-up for an additional 13 weeks. The primary outcome measures are the Vascular Dementia Assessment Scale-cognitive subscale and Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale. Secondary outcome measures include the Clinician’s Interview Based Impression of Change-Plus, CLOX, EXIT-25, Neuropsychiatric Inventory-Clinician rating scale, and Dementia Quality of Life questionnaire. Safety is assessed through adverse event reports and liver, renal, and coagulation studies. Primary and secondary outcome measures will be compared between treatment and placebo groups, using intention to treat and per protocol analyses. We hypothesise that a 52-week treatment of SLT will be clinically effective and well tolerated in participants with VaD or AD+CVD. This project will provide vital efficacy and safety data for this novel treatment approach to VaD. |
| first_indexed | 2024-04-09T23:36:52Z |
| format | Article |
| id | doaj.art-0b4176eb387644a5817397c32da611ac |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T23:36:52Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-0b4176eb387644a5817397c32da611ac2023-03-20T05:31:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular diseaseDiana KaramacoskaDaniel K. Y. ChanIsabella LeungJian-xun LiuHenry BrodatyPaul P. FaheyAlan BensoussanDennis H. ChangVascular dementia (VaD) accounts for 15–20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng C.A Mey, Ginkgo biloba L and Crocus sativus L extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention. A rigorous phase III clinical trial was developed with the aim of recruiting 238 patients diagnosed with mild to moderate probable VaD, or VaD mixed with Alzheimer’s disease (where cerebrovascular disease is the clinical dominant contributor to dementia, abbreviated as CVD+AD). Using a permuted block strategy, participants will be randomly allocated to receive SLT (120 mg bd) or placebo capsules for an intervention period of 52 weeks and will be followed-up for an additional 13 weeks. The primary outcome measures are the Vascular Dementia Assessment Scale-cognitive subscale and Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale. Secondary outcome measures include the Clinician’s Interview Based Impression of Change-Plus, CLOX, EXIT-25, Neuropsychiatric Inventory-Clinician rating scale, and Dementia Quality of Life questionnaire. Safety is assessed through adverse event reports and liver, renal, and coagulation studies. Primary and secondary outcome measures will be compared between treatment and placebo groups, using intention to treat and per protocol analyses. We hypothesise that a 52-week treatment of SLT will be clinically effective and well tolerated in participants with VaD or AD+CVD. This project will provide vital efficacy and safety data for this novel treatment approach to VaD.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016672/?tool=EBI |
| spellingShingle | Diana Karamacoska Daniel K. Y. Chan Isabella Leung Jian-xun Liu Henry Brodaty Paul P. Fahey Alan Bensoussan Dennis H. Chang Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease PLoS ONE |
| title | Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease |
| title_full | Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease |
| title_fullStr | Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease |
| title_full_unstemmed | Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease |
| title_short | Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer’s disease with cerebrovascular disease |
| title_sort | study protocol for a phase iii randomised controlled trial of sailuotong slt for vascular dementia and alzheimer s disease with cerebrovascular disease |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016672/?tool=EBI |
| work_keys_str_mv | AT dianakaramacoska studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT danielkychan studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT isabellaleung studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT jianxunliu studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT henrybrodaty studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT paulpfahey studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT alanbensoussan studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease AT dennishchang studyprotocolforaphaseiiirandomisedcontrolledtrialofsailuotongsltforvasculardementiaandalzheimersdiseasewithcerebrovasculardisease |